146
Participants
Start Date
November 13, 2017
Primary Completion Date
March 19, 2019
Study Completion Date
March 19, 2019
TransCon hGH
Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
The Liggins Institute, The University of Auckland, Grafton
Monash Children's Hospital, Clayton
Icahn School of Medicine at Mount Sinai, New York
NYU Winthrop Hospital, Mineola
University of Virginia Children's Hospital, Charlottesville
Children's Hospital of The King's Daughters, Norfolk
Nemours Children's Health System, Jacksonville
Tallahassee Memorial Hospital, Tallahassee
Orlando Health Inc., Orlando
University of Alabama, Birmingham
University of Mississippi Medical Center, Jackson
Cleveland Clinic Foundation, Cleveland
University of Iowa, Iowa City
Children's Minnesota, Saint Paul
University of Oklahoma Health Sciences Center, Oklahoma City
Children's Medical Center, Dallas
Cook Children's Medical Center, Fort Worth
Rocky Mountain Pediatric Endocrinology, Centennial
Neufeld Medical Group Inc., Los Angeles
Center of Excellence in Diabetes and Endocrinology, Sacramento
Children's Diabetes and Endocrine Center, Portland
Oregon Health & Science University, Portland
Dartmouth Hitchcock Medical Center, Lebanon
Stollery Children's Hospital, Edmonton
Ascendis Pharma Endocrinology Division A/S
INDUSTRY